| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Stefan N Willich | |
| Thomas Reinhold | |||
| Anne Berghöfer | |||
| P2860 | cites work | The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction- cost-effectiveness in relation to open access echocardiography | Q30482539 |
| 'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data | Q33261643 | ||
| The epidemiology of heart failure | Q34417319 | ||
| ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology | Q34830023 | ||
| Incidence and epidemiology of heart failure | Q36287940 | ||
| Comparative cost-effectiveness of B-type natriuretic peptide and echocardiography for predicting outcome in patients with congestive heart failure | Q40355102 | ||
| Life expectancy and health care expenditures: a new calculation for Germany using the costs of dying | Q40422673 | ||
| Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting | Q46456287 | ||
| Natriuretic peptides--new diagnostic markers in heart disease | Q46506279 | ||
| Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction | Q47932407 | ||
| Medical and economic long-term effects of B-type natriuretic peptide testing in patients with acute dyspnea | Q48128673 | ||
| Cost effectiveness of the B type natriuretic peptide, electrocardiography, and portable echocardiography for the assessment of patients from the community with suspected heart failure. | Q48267411 | ||
| Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population | Q48394651 | ||
| Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department | Q48430419 | ||
| Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea | Q48527726 | ||
| N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome | Q49145567 | ||
| Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. | Q51039466 | ||
| Ruling out heart failure in primary-care: The cost-benefit of pre-screening using NT-proBNP and QRS width | Q61716646 | ||
| Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study | Q77357169 | ||
| Frontiers in congestive heart failure: Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting | Q77596085 | ||
| [Acute heart failure: rational diagnostics in clinical practice and the emergency department] | Q79409013 | ||
| Is B-type natriuretic peptide-guided heart failure management cost-effective? | Q80356337 | ||
| Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: a retrospective study | Q81096607 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | German | Q188 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 1-10 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Herz | Q2143725 |
| P1476 | title | [Is the determination of biomarkers worth its price? Review of the literature taking brain natriuretic peptides (BNP) as an example]. | |
| P478 | volume | 35 |
| Q30318331 | Cardiac biomarkers in perioperative medicine : significance for noncardiac surgery patients |
| Q37880133 | Clinical applicability of B-type natriuretic peptide in patients with suspected heart failure in primary care in Spain: the PANAMA study |
| Q45795770 | Economic evidence in decision-making process in laboratory medicine |
| Q35036150 | How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? |
Search more.